Global Meningococcal Disease Vaccine Market, By Vaccine Serotype (MenACWY, MenB and Manic, MenC, MenA, MenAC, Others), Route of Administration (Parenteral, Others), Age Group (Infants (0 to 2 years), Children and Adults (2 years and above)), Vaccine Type (Polysaccharide, Conjugate, Combination), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Meningococcal disease is an uncommon infection caused by the bacteria Neisseria meningitidis that affects the lining of the brain, spinal cord, and blood. The germs that cause meningococcal disease transmit by saliva or spit, usually through direct contact with sick persons and subsequent contact. Meningococcal septicemia occurs when the meningococcal infection spreads to the bloodstream, causing bleeding into the skin and organs, fever and chills, vomiting and diarrhoea, and chilly hands and feet. Headache, stiff neck, heightened sensitivity to light, and feeling disoriented are some of the other symptoms. Protection against these infections is extremely crucial because they can swiftly turn lethal, causing major disabilities such as hearing loss or brain damage, or even death in just a few hours.
Data Bridge Market Research analyses that the meningococcal disease vaccine market was valued at USD 3.08 billion in 2021 and is expected to reach USD 6.60 billion by 2029, registering a CAGR of 10.0% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Vaccine Serotype (MenACWY, MenB and Manic, MenC, MenA, MenAC, Others), Route of Administration (Parenteral, Others), Age Group (Infants (0 to 2 years), Children and Adults (2 years and above)), Vaccine Type (Polysaccharide, Conjugate, Combination), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Serum Institute of India Pvt. Ltd. (India), Baxter (U.S.), Walvax Biotechnology Co., Ltd. (China), BIO-MED (India), Bio-Manguinhos (Brazil)
|
|
Market Opportunities
|
|
Market Definition
Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
Meningococcal Disease Vaccine Market Dynamics
Drivers
- Increasing prevalence of meningitis
The rising prevalence of meningitis is estimated to enhance the meningococcal disease vaccine market's growth rate. Meningitis is an inflammation of the brain and spinal cord's inner lining caused by infectious (viral, bacterial, and occasionally fungal) or non-infectious sources. Meningitis is a deadly disease with a quick onset of symptoms. Meningitis can cause significant brain damage in about half of the afflicted population if left untreated. Mental retardation, epilepsy, and deafness are only a few of the significant side effects. According to the Meningitis Research Foundation, enteroviruses are responsible for approximately 80% to 90% of meningitis cases in 2017, with the remaining 10% being caused by herpes virus, mumps, measles, and human immunodeficiency virus.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of meningococcal disease vaccine market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, increasing public-private partnerships to support the development of vaccines at low cost and rising level of disposable income will expand the meningococcal disease vaccine market. Additionally, the increasing prevalence of the meningococcal disease among young children and adolescents across the globe and increasing number of government initiatives to spread awareness are estimated to enhance the market’s growth rate.
Opportunities
- Increase in the number of research and development activities
The meningococcal disease vaccine market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the meningococcal disease vaccine market growth.
Moreover, increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the meningococcal disease vaccine market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the meningococcal disease vaccine market. Additionally, side effects of meningococcal disease vaccine and strict FDA guidelines for the drug approval of new drug will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This meningococcal disease vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the meningococcal disease vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Meningococcal disease vaccine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Meningococcal Disease Vaccine Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the meningococcal disease vaccine market. On the bright side, the meningococcal disease vaccine market will likely improve as respective government bodies have lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.
Recent Development
- In April, 2020, the U.S. Food and Drug Administration (FDA) announced the approval of Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older. MenQuadfi was developed to elicit and demonstrate a strong immunological response in people of all ages, and it was well tolerated. MenQuadfi is designed to safeguard men of all ages.
Global Meningococcal Disease Vaccine Market Scope
The meningococcal disease vaccine market is segmented on the basis of vaccine serotype, age group, vaccine type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Vaccine Serotype
- MenACWY
- MenB and Manic
- MenC
- MenA
- MenAC
- Others
Age Group
- Infants (0 to 2 years)
- Children and Adults (2 years and above)
Vaccine Type
- Polysaccharide
- Conjugate
- Combination
Route of Administration
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Meningococcal Disease Vaccine Market Regional Analysis/Insights
The meningococcal disease vaccine market is analyzed and market size insights and trends are provided by country, vaccine serotype, age group, vaccine type, route of administration, end-users and distribution channel as referenced above.
The countries covered in the meningococcal disease vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the meningococcal disease vaccine market because of the presence of key manufacture of the product and rising healthcare expenditure in this region. Additionally, high research and development expenditure and reduced incidence rate of meningitis will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to increased government awareness programs and rising healthcare expenditure in this region. Also, the growing number of patient population will further cushion the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Meningococcal Disease Vaccine Market Share Analysis
The meningococcal disease vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to meningococcal disease vaccine market.
Some of the major players operating in the meningococcal disease vaccine market are:
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Serum Institute of India Pvt. Ltd. (India)
- Baxter (U.S.)
- Walvax Biotechnology Co., Ltd. (China)
- BIO-MED (India)
- Bio-Manguinhos (Brazil)
SKU-